Indaptus Therapeutics Q1 2023 net loss $0.51/sh; cash $21.7M, runway into Q2 2024

Indaptus Therapeutics, Inc.

2024-Q1 EPS reported -$0.51

R&D expenses $1.9M (+$0.6M YoY); G&A $2.6M (+$0.5M YoY); net loss per share $0.51 vs $0.41.
Cash and equivalents $21.7M at March 31, 2023, down from $26.4M at Dec 31, 2022; cash runway into Q2 2024.
First patient dosed in Phase 1 trial of Decoy20 for solid tumors in March 2023; three trial sites activated.
Patent allowances in Brazil and India bring IP protection to 32 countries for Decoy platform.
Robert Martell, M.D., Ph.D. elected to Board of Directors in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Indaptus Therapeutics, Inc. reported first quarter ended March 31, 2023 results: EPS approximately $0.51.

Period: first quarter ended March 31, 2023
EPS: approximately $0.51
Result: reported results

Exact text from the filing

Loss per share for the three-month period ended March 31, 2023 was approximately $0.51 compared with approximately $0.41 for the three-month period ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.